Real-world evidence of baseline soluble CD25 as a prognostic biomarker and indicator of differential EGFR–TKI benefit in stage IV lung adenocarcinoma - Quiz - MDSpire

Real-world evidence of baseline soluble CD25 as a prognostic biomarker and indicator of differential EGFR–TKI benefit in stage IV lung adenocarcinoma

  • By

  • Huiru Guo

  • Lingshuang Liu

  • Veronika Lindberg

  • Yingjun Xue

  • Jan P. A. Baak

  • July 10, 2026

  • 0 min

Share

Original Source(s)

Real-world evidence of baseline soluble CD25 as a prognostic biomarker and indicator of differential EGFR–TKI benefit in stage IV lung adenocarcinoma

  • by Huiru Guo, Lingshuang Liu, Veronika Lindberg, Yingjun Xue, Jan P. A. Baak

  • July 10, 2026

Related Content

Case Report: Recurrent cerebral embolism secondary to direct cardiac invasion by lung adenocarcinoma

Safety and efficacy of DLL3 CAR-T cells armored with dnTGFBR2 in a subject with recurrent small-cell lung cancer: case report

Development and application of a prognostic model based on radiomics and artificial intelligence for patients with lung adenocarcinoma brain metastasis